Participant‐reported pain relief of 50% or greater · health problem or population
It is very uncertain whether summary of findings table ‐ Cannabis changes pain:number of participants reporting pain relief of 50% or greater… compared with placebo (very low certainty).
1 finding from 1 review
Patient Global Impression of Change much or very much improved · health problem or population
Summary of findings table ‐ Cannabis probably leads to higher PGIC:number of participants reporting much or very much improvement… compared with placebo (moderate certainty).
1 finding from 1 review
Health‐related quality of life. Mean change from baseline · health problem or population
1 finding from 1 review
Number withdrawn due to adverse events · health problem or population
Summary of findings table ‐ Cannabis may leads to higher withdrawn due to adverse events ( compared with placebo (low certainty).
1 finding from 1 review
SAEs · health problem or population
Summary of findings table ‐ Cannabis showed no clear difference in SAEs: number of participants with SAEs ( compared with placebo (low certainty).
1 finding from 1 review
Specific adverse events:nervous system disorder · health problem or population
Summary of findings table ‐ Cannabis may leads to higher specific AEs:number of participants reporting nervous system… compared with placebo (low certainty).
1 finding from 1 review
Adverse events: psychological disorders · health problem or population
Summary of findings table ‐ Cannabis may leads to higher specific AEs: number of participants reporting psychiatric disorders ( compared with placebo (low certainty).
1 finding from 1 review
Specific AEs: number of participants reporting drug tolerance ( · health problem or population
It is very uncertain whether summary of findings table ‐ Cannabis changes specific AEs: number of participants reporting drug tolerance ( compared with placebo (very low certainty).
1 finding from 1 review
Proportion of participants with sustained remission (as defined by study investigators) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every 4 weeks probably leads to higher proportion of participants with sustained remission (as defined by… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every 4 weeks showed no clear difference in adverse events at ≥ 12 months compared with placebo (moderate certainty).
1 finding from 1 review
Proportion of participants with sustained remission (as defined by study investigators) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly probably leads to higher proportion of participants with sustained remission (as defined by… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Proportion of participants with relapse‐free survival at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly probably leads to higher proportion of participants with relapse‐free survival at ≥ 12 months compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Proportion of all‐cause mortality at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Mean time to first relapse after induction of remission (weeks) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Proportion of participants who did not need escape therapy (as defined by study investigators) · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly probably leads to higher proportion of participants who did not need escape therapy (as… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
QoL · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly probably leads to higher mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly probably leads to higher mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Proportion of participants with relapse‐free survival at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every 4 weeks probably leads to higher proportion of participants with relapse‐free survival at ≥ 12 months compared with placebo (moderate certainty).
1 finding from 1 review